Pembrolizumab & Endometrial cancer (EC) (MMR-d/MSI-H)

FDA status:

In the context of Pembrolizumab & Endometrial cancer (EC) (MMR-d/MSI-H), pembrolizumab has an FDA approved indication as monotherapy for patients with advanced Endometrial cancer (EC) (MMR-d/MSI-H), as determined by an FDA‑approved test, whose disease has progressed following prior systemic therapy in any setting and who are not candidates for curative surgery or radiation. This is a tumor‑specific MSI‑H/dMMR indication in EC and is separate from the earlier tissue‑agnostic MSI‑H/dMMR solid‑tumor approval

EMA status:

In the EU, pembrolizumab as monotherapy is approved for adults with advanced or recurrent [Endometrial cancer (EC) …